Metabolic modulation by the HCMV UL38 gene

HCMV UL38 基因的代谢调节

基本信息

  • 批准号:
    10112826
  • 负责人:
  • 金额:
    $ 38.5万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-02-21 至 2025-01-31
  • 项目状态:
    未结题

项目摘要

Human Cytomegalovirus (HCMV) is a major cause of congenital birth defects and causes severe disease in a wide variety of immunosuppressed patient populations, including hematological cancer patients and transplant recipients. We have found that HCMV institutes a pro-viral metabolic program that drives numerous cellular metabolic activities to support the production of viral progeny. More recently, we find that the HCMV UL38 protein is necessary and sufficient to drive many aspects of HCMV-induced metabolic remodeling, and we hypothesize that UL38 supports infection through its inhibition of the TSC2 tumor suppressor protein to induce metabolic modulation. We will test this hypothesis in Aim 1 by elucidating how UL38-TSC2-mediated metabolic remodeling contributes to HCMV infection. In addition, we find that HCMV-induces the expression of neuronal enolase 2 (ENO2), which we find is important for robust HCMV infection. We hypothesize that ENO2 induction is critical for HCMV-mediated metabolic modulation, which we will test in Aim 2. Lastly, we find that both HCMV infection and UL38 expression sensitizes cells to metabolic perturbations, revealing vulnerabilities that could potentially be targeted therapeutically. We hypothesize that HCMV infection and UL38 expression induces a metabolically rigid state that sensitizes cells to metabolic challenges, a hypothesis we will test in Aim 3. The proposed work will broaden our understanding of an important host pathogen interaction, and given that these processes are essential for productive infection, the proposed experiments will highlight novel targets for therapeutic intervention.
人巨细胞病毒(HCMV)是先天性出生缺陷的主要原因,并在婴儿中引起严重疾病。 广泛的免疫抑制患者人群,包括血液癌症患者和移植 受惠人士我们已经发现,HCMV建立了一个前病毒代谢程序,驱动许多细胞凋亡, 代谢活性以支持病毒后代的产生。最近,我们发现HCMV UL 38 蛋白质是必要的,足以驱动HCMV诱导的代谢重塑的许多方面,我们 假设UL 38通过其抑制TSC 2肿瘤抑制蛋白来支持感染, 代谢调节我们将在目的1中通过阐明UL 38-TSC 2介导的代谢调节是如何被激活的来检验这一假设。 重塑有助于HCMV感染。此外,我们发现HCMV诱导神经元表达, 烯醇化酶2(ENO 2),我们发现其对于强HCMV感染是重要的。我们假设ENO 2诱导 对于HCMV介导的代谢调节至关重要,我们将在目标2中进行测试。最后,我们发现HCMV 感染和UL 38表达使细胞对代谢紊乱敏感,揭示了可能 有可能成为治疗靶点。我们假设HCMV感染和UL 38表达诱导了一种新的免疫应答。 代谢刚性状态,使细胞对代谢挑战敏感,我们将在目标3中测试这一假设。的 拟议的工作将扩大我们对一个重要的宿主病原体相互作用的理解,并考虑到这些 过程是必不可少的生产性感染,拟议的实验将突出新的目标, 治疗干预

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JOSHUA C MUNGER其他文献

JOSHUA C MUNGER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JOSHUA C MUNGER', 18)}}的其他基金

Metabolic modulation by the HCMV UL38 gene
HCMV UL38 基因的代谢调节
  • 批准号:
    10327734
  • 财政年份:
    2020
  • 资助金额:
    $ 38.5万
  • 项目类别:
Metabolic modulation by the HCMV UL38 gene
HCMV UL38 基因的代谢调节
  • 批准号:
    10553210
  • 财政年份:
    2020
  • 资助金额:
    $ 38.5万
  • 项目类别:
Metabolic modulation by the HCMV UL38 gene
HCMV UL38 基因的代谢调节
  • 批准号:
    10199231
  • 财政年份:
    2020
  • 资助金额:
    $ 38.5万
  • 项目类别:
HCMV-mediated repurposing of AMPK & CaMKK signaling for productive infection
HCMV 介导的 AMPK 的再利用
  • 批准号:
    9765147
  • 财政年份:
    2016
  • 资助金额:
    $ 38.5万
  • 项目类别:
Metabolic regulatory mechanisms essential for Human Cytomegalovirus replication
人类巨细胞病毒复制所必需的代谢调节机制
  • 批准号:
    8459347
  • 财政年份:
    2010
  • 资助金额:
    $ 38.5万
  • 项目类别:
Metabolic regulatory mechanisms essential for Human Cytomegalovirus replication
人类巨细胞病毒复制所必需的代谢调节机制
  • 批准号:
    7899310
  • 财政年份:
    2010
  • 资助金额:
    $ 38.5万
  • 项目类别:
Metabolic regulatory mechanisms essential for Human Cytomegalovirus replication
人类巨细胞病毒复制所必需的代谢调节机制
  • 批准号:
    8064343
  • 财政年份:
    2010
  • 资助金额:
    $ 38.5万
  • 项目类别:
Metabolic regulatory mechanisms essential for Human Cytomegalovirus replication
人类巨细胞病毒复制所必需的代谢调节机制
  • 批准号:
    8259814
  • 财政年份:
    2010
  • 资助金额:
    $ 38.5万
  • 项目类别:

相似海外基金

Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
  • 批准号:
    23K18186
  • 财政年份:
    2023
  • 资助金额:
    $ 38.5万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
  • 批准号:
    10560883
  • 财政年份:
    2023
  • 资助金额:
    $ 38.5万
  • 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10730692
  • 财政年份:
    2021
  • 资助金额:
    $ 38.5万
  • 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
  • 批准号:
    21K06459
  • 财政年份:
    2021
  • 资助金额:
    $ 38.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10189880
  • 财政年份:
    2021
  • 资助金额:
    $ 38.5万
  • 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
  • 批准号:
    2404261
  • 财政年份:
    2020
  • 资助金额:
    $ 38.5万
  • 项目类别:
    Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10222540
  • 财政年份:
    2020
  • 资助金额:
    $ 38.5万
  • 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10669717
  • 财政年份:
    2020
  • 资助金额:
    $ 38.5万
  • 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
  • 批准号:
    20K10713
  • 财政年份:
    2020
  • 资助金额:
    $ 38.5万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10174522
  • 财政年份:
    2020
  • 资助金额:
    $ 38.5万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了